Table of contents
July 2005 Vol 5 No 7
In this issue
p495 | doi:10.1038/nrc1659
Research Highlights
MicroRNA: Friend or foe?
p497 | doi:10.1038/nrc1658
Immunotherapy: Don't peak too soon...
p498 | doi:10.1038/nrc1656
In the news
A powerful argument?
p498 | doi:10.1038/nrc1661
Diagnostics: Auspicious antigens
p499 | doi:10.1038/nrc1655
Trial Watch
GIST genotyping
p499 | doi:10.1038/nrc1665
Mouse models: Knocking in is the new knocking out
p500 | doi:10.1038/nrc1657
Angiogenesis: All tied up
p500 | doi:10.1038/nrc1664
Immunology: B cells lead the way in tumour progression
p501 | doi:10.1038/nrc1662
Structural biology: Spirals and curls
p502 | doi:10.1038/nrc1654
In brief
Genetics | Free Radicals | Metastasis | Protein Kinases
p502 | doi:10.1038/nrc1660
Chemoprevention: A cellular chill-out pill?
p503 | doi:10.1038/nrc1663
Trial Watch
Successful discontinuation | 30 years on
p503 | doi:10.1038/nrc1666
Reviews
The role of focal-adhesion kinase in cancer — a new therapeutic opportunity
Gordon W. McLean, Neil O. Carragher, Egle Avizienyte, Jeff Evans, Valerie G. Brunton & Margaret C. Frame
p505 | doi:10.1038/nrc1647
Repopulation of cancer cells during therapy: an important cause of treatment failure
John J. Kim & Ian F. Tannock
p516 | doi:10.1038/nrc1650
The sweet and sour of cancer: glycans as novel therapeutic targets
Mark M. Fuster & Jeffrey D. Esko
p526 | doi:10.1038/nrc1649
The anaemia of cancer: death by a thousand cuts
Jerry L. Spivak
p543 | doi:10.1038/nrc1648
Perspectives
Opinion
Neurofibromatosis type 1 — a model for nervous system tumour formation?
Joshua B. Rubin & David H. Gutmann
p557 | doi:10.1038/nrc1653
Opinion
Cancer in xeroderma pigmentosum and related disorders of DNA repair
James E. Cleaver
p564 | doi:10.1038/nrc1652
Opinion
Killing time for cancer cells
Shoshana Klein, Frank McCormick & Alexander Levitzki
p573 | doi:10.1038/nrc1651
Correction: ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors
Nancy E. Hynes & Heidi A. Lane
p580 | doi:10.1038/nrc1667